Healthcare stocks languish in 1996

Article

U.S. healthcare stocks generally turned in a lackluster performancein 1996, according to the results of Annual Healthcare IndustryReport, a year-end survey issued this week by WDI Capital Marketsof Hilton Head, SC. Overall, healthcare stocks were up a

U.S. healthcare stocks generally turned in a lackluster performancein 1996, according to the results of Annual Healthcare IndustryReport, a year-end survey issued this week by WDI Capital Marketsof Hilton Head, SC. Overall, healthcare stocks were up a meager2.7% in 1996, compared with growth of 40% in 1995. The industrywas down 4.7% in 1994 and 9.4% in 1993.

Within medical imaging, the imaging services segment saw its sharesgrow 43.5% for the year, a performance that led all healthcaresegments but was still down several points from 1995's hefty growthof 52%. The segment was driven by growth in shares of Health Images,which gained 129%; Alliance Imaging, which grew 105%; MedicalResources, up 103%; and SMT Health Services, up 95%.

The imaging devices segment ticked up a mere 4.3%, compared withgrowth of 75.9% in 1995, according to the WDI survey. Gains of97% by both Acuson and ADAC Laboratories were offset by a 47%decline at Elscint (including a 5-for-1 reverse stock split),a 41% drop in Fischer Imaging shares, and a 43% decline in Norland'sstock. Other firms whose shares posted gains in 1996 include OECMedical, up 54%; Lunar, up 27%; and Hologic, up 21%.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.